News of the WeekDRUG PATENTS

Universities, NIH Hear the Price Isn't Right on Essential Drugs

+ See all authors and affiliations

Science  27 Apr 2001:
Vol. 292, Issue 5517, pp. 614-615
DOI: 10.1126/science.292.5517.614

You are currently viewing the summary.

View Full Text

Summary

The University of Minnesota is in the middle of an international debate over whether the public should get back some of the profits generated by biomedical research it has funded. A major driving force has been the cost and availability of AIDS drugs in developing countries--an issue on which advocates of limiting drug profits claimed a victory last week in South Africa. And the U.S. National Institutes of Health is being drawn reluctantly into the fray by a congressional directive to identify big moneymaking drugs derived from NIH-funded research.